SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
企業コードSABS
会社名SAB Biotherapeutics Inc
上場日Jan 12, 2021
最高経営責任者「CEO」Reich (Samuel J)
従業員数63
証券種類Ordinary Share
決算期末Jan 12
本社所在地777 W 41St St
都市MIAMI BEACH
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号33140
電話番号13058452813
ウェブサイトhttps://www.sab.bio/
企業コードSABS
上場日Jan 12, 2021
最高経営責任者「CEO」Reich (Samuel J)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし